Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma.
Polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles (NP) were shown to enable the transport of a number of drugs including the anti-tumour antibiotic doxorubicin (DOX) across the blood-brain barrier (BBB) to the brain after intravenous administration and to considerably reduce the growth of brain tumours in rats. The objective of the present study was to evaluate the acute toxicity of DOX associated with polysorbate 80-coated NP in healthy rats and to establish a therapeutic dose range for this formulation in rats with intracranially implanted 101/8 glioblastoma. Single intravenous administration of empty poly(butyl cyanoacrylate) NP in the dose range 100-400 mg/kg did not cause mortality within the period of observation. NP also did not affect body weight or weight of internal organs. Association of DOX with poly(butyl cyanoacrylate) NP did not produce significant changes of quantitative parameters of acute toxicity of the anti-tumour agent. Likewise, the presence of polysorbate 80 in the formulations was not associated with changes in toxicity compared with free or nanoparticulate drug. Dose regimen of 3x1.5 mg/kg on days 2, 5, 8 after tumour implantation did not cause drug-induced mortality. The results in tumour-bearing rats were similar to those in healthy rats. These results demonstrate that the toxicity of DOX bound to NP was similar or even lower than that of free DOX.
Gelperina
S E
SE
Moscow Institute of Medical Ecology, Sympheropolsky Blvd. 8, Moscow, Russia.
Khalansky
A S
AS
Skidan
I N
IN
Smirnova
Z S
ZS
Bobruskin
A I
AI
Severin
S E
SE
Turowski
B
B
Zanella
F E
FE
Kreuter
J
J
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity*; D001835:Body Weight / Q000187:drug effects; D001932:Brain Neoplasms / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity*; D004337:Drug Carriers; D004659:Enbucrilate / Q000633:toxicity*; D005079:Excipients; D005909:Glioblastoma / Q000188:drug therapy; D008136:Longevity / Q000187:drug effects; D020714:Maximum Tolerated Dose; D036103:Nanotechnology; D009368:Neoplasm Transplantation; D009929:Organ Size / Q000187:drug effects; D011136:Polysorbates; D051381:Rats; D017208:Rats, Wistar; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D004337:Drug Carriers; D005079:Excipients; D011136:Polysorbates; D004317:Doxorubicin; D004659:Enbucrilate